Literature DB >> 11250175

Endovascular stenting of superficial femoral artery stenosis and occlusions: results and risk factor analysis.

S W Cheng1, A C Ting, J Wong.   

Abstract

PURPOSE: To determine the early and midterm results of femoro-popliteal angioplasty with adjunctive stenting and to identify factors affecting early and continuing success.
METHODS: Sixty-nine consecutive balloon angioplasty procedures on the superficial femoral artery (SFA) were performed in 60 limbs and 55 patients in the operating theater. Fifty-two percent of lesions were occlusions, and 87% involved the distal half or the whole segment of the SFA. Immediate endovascular stenting was used in all procedures, involving the placement of 105 stents, with a mean stented length of 13.8 cm. Twenty-nine procedures (43%) were performed for critical ischemia. Three-monthly duplex ultrasound was used for follow up assessment, with stenosis of > 50% defined as the endpoint for failure. The patient demographic and biochemical data, and procedural details were correlated with success criteria according to Society of Vascular Surgery standards.
RESULTS: Initial technical success by intent to treat was 92%, with four procedure-related complications and no deaths. Initial success by anatomic, hemodynamic and clinical criteria were 98.3, 96.7 and 93.3% respectively (92.2, 90.6 and 87.5% by intent to treat). Cumulative primary patency at 6, 12, and 24 months was 73.1, 62.6 and 53.8%, and secondary patency 84.9, 72.1 and 72.1% correspondingly. Significant factors relating to inferior patency were occlusions, stented segment length > 10 cm, procedure in claudicants, and the use of the Memotherm stent.
CONCLUSIONS: Angioplasty and stenting of the superficial femoral artery has acceptable primary and secondary patency rates even in the presence of long stenosis and occlusions. A duplex surveillance program is recommended for early detection and timely treatment of restenosis.

Entities:  

Mesh:

Year:  2001        PMID: 11250175     DOI: 10.1016/s0967-2109(00)00109-5

Source DB:  PubMed          Journal:  Cardiovasc Surg        ISSN: 0967-2109


  7 in total

Review 1.  Superficial femoral artery: current treatment options.

Authors:  Gunnar Tepe; Jörg Schmehl; Stephan Heller; Benjamin Wiesinger; Claus D Claussen; Stephan H Duda
Journal:  Eur Radiol       Date:  2006-02-18       Impact factor: 5.315

2.  Percutaneous treatment of complete chronic occlusions of the superficial femoral artery.

Authors:  D Laganà; G Carrafiello; M Dizonno; M Barresi; R Caronno; P Castelli; C Fugazzola
Journal:  Radiol Med       Date:  2008-05-20       Impact factor: 3.469

3.  Comparison of in vitro human endothelial cell response to self-expanding stent deployment in a straight and curved peripheral artery simulator.

Authors:  Ríona Ní Ghriallais; Laoise McNamara; Mark Bruzzi
Journal:  J R Soc Interface       Date:  2013-01-30       Impact factor: 4.118

4.  "Full metal jacket" with direct stenting of complete chronic occlusions of the superficial femoral artery.

Authors:  D Laganà; G Carrafiello; M Barresi; D Lumia; M Dizonno; F A Vizzari; F Fontana; M Mangini; P Castelli; C Fugazzola
Journal:  Radiol Med       Date:  2011-01-12       Impact factor: 3.469

Review 5.  Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammation.

Authors:  Louis L Nguyen
Journal:  J Vasc Surg       Date:  2007-06       Impact factor: 4.268

6.  Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.

Authors:  Michael D Dake; Gary M Ansel; Michael R Jaff; Takao Ohki; Richard R Saxon; H Bob Smouse; Lindsay S Machan; Scott A Snyder; Erin E O'Leary; Anthony O Ragheb; Thomas Zeller
Journal:  Circulation       Date:  2016-03-11       Impact factor: 29.690

7.  Rhombic-Shaped Channel Stent with Enhanced Drug Capacity and Fatigue Life.

Authors:  Hao-Ming Hsiao; Cheng-Han Lin; Yung-Kang Shen; Tzu-Yun Chou; Yen-Yu Hsu
Journal:  Micromachines (Basel)       Date:  2017-12-24       Impact factor: 2.891

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.